|
Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
Travel, Accommodations, Expenses - Aduro Biotech |
|
|
No Relationships to Disclose |
|
|
Employment - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
Research Funding - Aduro Biotech |
Patents, Royalties, Other Intellectual Property - Aduro Biotech |
Travel, Accommodations, Expenses - Aduro Biotech |
|
|
Research Funding - Novo Nordisk |
Travel, Accommodations, Expenses - Novo Nordisk |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Genentech; Gilead Sciences |
Leadership - Prima BioMed |
Stock and Other Ownership Interests - Gilead Sciences |
Consulting or Advisory Role - Astellas Pharma; Prima BioMed; Vaxart |
Research Funding - LigoCyte Pharmaceuticals |
|
|
Employment - Aduro Biotech |
Leadership - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
|
|
Employment - Aduro Biotech |
Leadership - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
|
|
Research Funding - Aduro Biotech |
Patents, Royalties, Other Intellectual Property - Aduro Biotech |
|
|
No Relationships to Disclose |